CN111778205B - 人心肌细胞分离试剂、培养基、分离方法和培养方法 - Google Patents
人心肌细胞分离试剂、培养基、分离方法和培养方法 Download PDFInfo
- Publication number
- CN111778205B CN111778205B CN201910275447.2A CN201910275447A CN111778205B CN 111778205 B CN111778205 B CN 111778205B CN 201910275447 A CN201910275447 A CN 201910275447A CN 111778205 B CN111778205 B CN 111778205B
- Authority
- CN
- China
- Prior art keywords
- human
- blebbistatin
- culture
- cell
- cardiomyocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 100
- 238000000926 separation method Methods 0.000 title claims abstract description 29
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 17
- 210000004413 cardiac myocyte Anatomy 0.000 title claims description 100
- 239000001963 growth medium Substances 0.000 title abstract description 16
- 238000012136 culture method Methods 0.000 title abstract description 9
- LZAXPYOBKSJSEX-GOSISDBHSA-N (S)-blebbistatin Chemical compound O=C([C@]1(O)CC2)C3=CC(C)=CC=C3N=C1N2C1=CC=CC=C1 LZAXPYOBKSJSEX-GOSISDBHSA-N 0.000 claims abstract description 66
- 230000002107 myocardial effect Effects 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 75
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 12
- 229930182555 Penicillin Natural products 0.000 claims description 11
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 11
- 229940049954 penicillin Drugs 0.000 claims description 11
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 11
- 229960005322 streptomycin Drugs 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 7
- 229960003624 creatine Drugs 0.000 claims description 6
- 239000006046 creatine Substances 0.000 claims description 6
- 229940054269 sodium pyruvate Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 abstract description 25
- LYWLZINJPRNWFF-GOSISDBHSA-N (3aS)-1-(4-aminophenyl)-3a-hydroxy-6-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-one Chemical compound Cc1ccc2N=C3N(CC[C@@]3(O)C(=O)c2c1)c1ccc(N)cc1 LYWLZINJPRNWFF-GOSISDBHSA-N 0.000 abstract description 7
- 239000006143 cell culture medium Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 22
- 108010085895 Laminin Proteins 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000002955 isolation Methods 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- WTHKAJZQYNKTCJ-UHFFFAOYSA-N 4-methyl-N-(phenylmethyl)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NCC1=CC=CC=C1 WTHKAJZQYNKTCJ-UHFFFAOYSA-N 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- RLCLASQCAPXVLM-NSHDSACASA-N CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O Chemical compound CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O RLCLASQCAPXVLM-NSHDSACASA-N 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000003505 Myosin Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 210000003771 C cell Anatomy 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- BQMPVGMHZKZPBH-BYZBDTJCSA-N (3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O BQMPVGMHZKZPBH-BYZBDTJCSA-N 0.000 description 2
- RGPUSZZTRKTMNA-UHFFFAOYSA-N 1-benzofuran-7-carbaldehyde Chemical compound O=CC1=CC=CC2=C1OC=C2 RGPUSZZTRKTMNA-UHFFFAOYSA-N 0.000 description 2
- 229940121819 ATPase inhibitor Drugs 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 108030001204 Myosin ATPases Proteins 0.000 description 2
- 102000005640 Myosin Type II Human genes 0.000 description 2
- 108010045128 Myosin Type II Proteins 0.000 description 2
- 229920002334 Spandex Polymers 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000162 organ preservation solution Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004759 spandex Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HOHIAEPXOHCCGW-UHFFFAOYSA-N 2-aminoethanesulfonic acid Chemical compound NCCS(O)(=O)=O.NCCS(O)(=O)=O HOHIAEPXOHCCGW-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- WOAPPPQSRICWMX-DFWYDOINSA-N N[C@@H](CCC(N)=O)C(=O)O.C(C)S(=O)(=O)O Chemical compound N[C@@H](CCC(N)=O)C(=O)O.C(C)S(=O)(=O)O WOAPPPQSRICWMX-DFWYDOINSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical group [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- LZAXPYOBKSJSEX-UHFFFAOYSA-N blebbistatin Chemical compound C1CC2(O)C(=O)C3=CC(C)=CC=C3N=C2N1C1=CC=CC=C1 LZAXPYOBKSJSEX-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/46—Amines, e.g. putrescine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
组分 | 浓度 |
胶原酶II | 300U/ml |
CaCl<sub>2</sub> | 0.015mM |
组分 | 含量 |
无钙台式液 | 36ml |
胎牛血清 | 4ml |
Claims (2)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910275447.2A CN111778205B (zh) | 2019-04-04 | 2019-04-04 | 人心肌细胞分离试剂、培养基、分离方法和培养方法 |
US17/594,072 US20220169989A1 (en) | 2019-04-04 | 2020-04-02 | Human cardiomyocyte separation reagent, culture medium, separation method, and culture method |
EP20781916.0A EP3967751A4 (en) | 2019-04-04 | 2020-04-02 | HUMAN CARDIOMYOCYTE SEPARATION REAGENT, CULTURE MEDIUM, SEPARATION PROCEDURE AND CULTURE PROCEDURE |
PCT/CN2020/082949 WO2020200272A1 (zh) | 2019-04-04 | 2020-04-02 | 人心肌细胞分离试剂、培养基、分离方法和培养方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910275447.2A CN111778205B (zh) | 2019-04-04 | 2019-04-04 | 人心肌细胞分离试剂、培养基、分离方法和培养方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111778205A CN111778205A (zh) | 2020-10-16 |
CN111778205B true CN111778205B (zh) | 2022-09-30 |
Family
ID=72664961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910275447.2A Active CN111778205B (zh) | 2019-04-04 | 2019-04-04 | 人心肌细胞分离试剂、培养基、分离方法和培养方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220169989A1 (zh) |
EP (1) | EP3967751A4 (zh) |
CN (1) | CN111778205B (zh) |
WO (1) | WO2020200272A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115698263A (zh) * | 2020-04-09 | 2023-02-03 | 青岛百洋智心科技有限公司 | 用于心肌细胞冻存的组合物 |
CN113424816A (zh) * | 2021-04-07 | 2021-09-24 | 上海慧灯医疗科技有限公司 | 一种心肌细胞冻存液及其制备方法 |
WO2024050139A1 (en) * | 2022-09-02 | 2024-03-07 | AnaBios Corporation | Therapeutic uses of cardiac myosin inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101481415B (zh) * | 2009-02-04 | 2010-05-12 | 山东农业大学 | 一种新型prrs病毒受体及该受体的阻断抑制剂 |
US20110212480A1 (en) * | 2010-02-26 | 2011-09-01 | Kyle Louis Kolaja | Use of primary human cardiomyocytes |
WO2013063305A2 (en) * | 2011-10-25 | 2013-05-02 | Mount Sinai School Of Medicine | Directed cardiomyocyte differentiation of stem cells |
JP2017108705A (ja) * | 2015-12-18 | 2017-06-22 | 国立大学法人京都大学 | 心筋細胞の製造方法 |
-
2019
- 2019-04-04 CN CN201910275447.2A patent/CN111778205B/zh active Active
-
2020
- 2020-04-02 EP EP20781916.0A patent/EP3967751A4/en active Pending
- 2020-04-02 WO PCT/CN2020/082949 patent/WO2020200272A1/zh unknown
- 2020-04-02 US US17/594,072 patent/US20220169989A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3967751A1 (en) | 2022-03-16 |
EP3967751A4 (en) | 2022-12-21 |
US20220169989A1 (en) | 2022-06-02 |
CN111778205A (zh) | 2020-10-16 |
WO2020200272A1 (zh) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111778205B (zh) | 人心肌细胞分离试剂、培养基、分离方法和培养方法 | |
JP6681825B2 (ja) | 多能性幹細胞から機能的心筋へと直接分化させる方法 | |
CN103409368B (zh) | 干细胞及胚胎来源的心肌细胞及推定的心肌细胞的纯化方法 | |
WO2018143258A1 (ja) | 多分化能性幹細胞増殖促進剤 | |
TW200521234A (en) | Method of single cell culture of undifferentiated human embryonic stem cells | |
WO2012117333A1 (en) | Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof | |
CN102787094B (zh) | 培养基、细胞培养用试剂盒及细胞培养方法 | |
JP2009539378A5 (zh) | ||
EP3770250A1 (en) | Differentiation promoter for pluripotent stem cells | |
US20130295669A1 (en) | Method for controlling binding of cells to a substrate | |
EP4083186A1 (en) | Cell growth regulator | |
RU2012107674A (ru) | Биотрансплантат для восстановления объема костной ткани при дегенеративных заболеваниях и травматических повреждениях костей и способ его получения | |
RU2391399C2 (ru) | Способ получения клеточной матрицы кожи | |
KR101656761B1 (ko) | 다능성 줄기 세포 및 심근 세포 이외의 분화성 세포에 대해 세포사멸을 유도하는 방법 | |
EP3284817A1 (en) | Human sebocyte precursor cells, human sebocytes and in vitro methods for obtaining the same from human induced pluripotent stem cells (hipsc) | |
US11395863B2 (en) | Modification method for sheet-shaped cell culture | |
EP3861103A1 (en) | Amniotic fluid cell-derived extracellular matrix and uses thereof | |
US20190161737A1 (en) | Process for continuous cell culture of cancer cells and cancer stem cells | |
EP3864137A1 (en) | Compositions and methods for cell culture | |
JP2010004796A (ja) | 分化抑制剤、分化抑制基材及び分化抑制方法並びにその使用 | |
KR20140097878A (ko) | 식물 줄기세포 또는 식물 역분화 줄기 세포의 추출물을 이용한 맞춤형 만능줄기세포의 유도 방법 및 상기 방법에 의해 제조된 만능줄기세포 | |
CN116769705A (zh) | 一种用于毛囊活化的间充质干细胞培养试剂 | |
CN102787093A (zh) | 培养基、细胞培养用试剂盒及细胞培养方法 | |
US20190151371A1 (en) | Process for continuous cell culture of islet cells | |
US20050054099A1 (en) | Matrix derived from whole organ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220507 Address after: 266000 room 256, building 1, No. 88, Kaifeng Road, Shibei District, Qingdao, Shandong Applicant after: Qingdao Baiyang Zhixin Technology Co.,Ltd. Address before: 100037 Beijing City, Xicheng District No. 167 North Applicant before: FUWAI HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231211 Address after: 518000, Building F, Zhigu R&D Building, Shuguang Community, Xili Street, Nanshan District, Shenzhen City, Guangdong Province, China 1501 Patentee after: Shenzhen Baiyang Zhixin Medical Research Co.,Ltd. Address before: Room 256, Building 1, No. 88 Kaifeng Road, Shibei District, Qingdao City, Shandong Province, 266000 Patentee before: Qingdao Baiyang Zhixin Technology Co.,Ltd. |